•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Cerenome, Inc. (CNSY) Q3 2026 Earnings Call Transcript
Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting
Cerenome (CNSY) Reports Q3 Loss, Beats Revenue Estimates
Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress
Cerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16
Cerenome Appoints Director Ron Andrews as Chief Business Officer
Cerenome Secures National In-Network Agreement with Aetna for CNSide®
Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma
Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases
New Strong Sell Stocks for October 22nd
Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™
New Strong Sell Stocks for October 15th
Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests
Cerenome Launches CNSide® CSF Molecular Profile Tests
Cerenome, Inc. (CNSY) Discusses Diagnostic Division Update and Progress on C-INSIDE Platform Transcript
Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
Cerenome to Hold CNSide® Business Update Call on September 30, 2026
Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives
Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment